جست‌وجوی استاد و پژوهشگر

Jonathan S. Serodyمشاهده پروفایل

استاد

• Transplantation Immunology
• Graft-versus-Host Disease (GVHD)
• Cellular Therapy
• +۷ مورد دیگر

Jonathan S. Serody, MD, serves as the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Medicine. He holds multiple leadership positions including Division Chief of Hematology, Associate Director for Translational Science at the UNC Lineberger Comprehensive Cancer Center, and Director of the Cellular Therapy Program. His clinical work focuses on bone marrow and stem cell transplantation, with expertise in leukemia, lymphoma, and malignant hematology. Elizabeth Thomas Professor of Medicine, Microbiology and Immunology (2006-present) Division Chief, Hematology (current) Associate Director for Translational Science, UNC Lineberger Comprehensive Cancer Center Director, Cellular Therapy Program Member, UNC Lineberger Comprehensive Cancer Center Dr. Serody's research program centers on transplantation immunology and cancer immunotherapy development. His laboratory pioneered key discoveries in graft-versus-host disease (GVHD) pathogenesis, including the critical role of chemokines in T-cell migration during GVHD and the function of regulatory T-cells in organ-specific GVHD. More recently, his work has expanded to developing novel immunotherapies for solid tumors, with significant contributions to CAR-T cell therapy enhancement through STING pathway activation and nanoparticle delivery systems. First demonstrated chemokine involvement in GVHD effector phase Discovered CCR5's role in CD4+/CD8+ T-cell differentiation during GVHD Identified Th17 cells as mediators of multi-organ GVHD Developed CAR-T cells from Th17/Tc17 cells combined with STING agonists for solid tumors Discovered NLRP3's role in blocking cancer vaccine efficacy through MDSC recruitment Established B-cell importance in immune checkpoint inhibitor response for breast cancer Dr. Serody's laboratory maintains active collaborations with multiple research groups including the Van Deventer laboratory, CVI, and Dr. Charles Perou's lab. His team has developed advanced imaging techniques for tracking immune cell migration in vivo, including intravital microscopy of eGFP transgenic T-cells. Current clinical trials in his program include testing HER-2/neu vaccine therapy combined with conventional treatment for metastatic breast cancer, with promising early survival data. Awarded the prestigious Hyman L. Battle Distinguished Cancer Research Award in 2023, Dr. Serody maintains editorial roles with Blood (2011-present) and previously with Journal of Clinical Oncology (2009-2012). His leadership extends to serving on the Leukemia and Lymphoma Society TRP Grant Review Group since 2005 and as member of the SPORE Parent Committee. As clinical director of the Advanced Cellular Therapeutics Facility (recently accredited without deficiency citations by the Foundation for the Accreditation of Cellular Therapy), Dr. Serody oversees cutting-edge cellular therapy programs. His educational background includes MD from University of Virginia (1986), residency in Internal Medicine at UNC Chapel Hill (1989), and fellowships in Hematology/Oncology (1994), Infectious Diseases (1992), and Bone Marrow Transplantation at Fred Hutchinson Cancer Research Center (1993).

Eva Riethmacherمشاهده پروفایل

استادیار

• Cancer development and progression
• Inflammatory bowel disease
• Mouse models in disease development
• +۶ مورد دیگر

Eva Riethmacher is an Assistant Professor at Nazarbayev University School of Medicine (NUSOM) in Kazakhstan, where she has been working since February 2016. She serves as the program director for the Ph.D. program in Biomedical Sciences at NUSOM. Prior to joining Nazarbayev University, she worked at the Faculty of Medicine, University of Southampton, UK (2008-2016), was a Senior Scientist at ZMNH, Hamburg, Germany (1999-2008), and completed postdoctoral training at MDC, Berlin, Germany (1995-1999) and MDL/MPI, Cologne, Germany (1993-1995). Dr. Riethmacher earned her PhD from the University of Cologne in 1993 and completed her Diploma at the same institution in 1989. Her academic journey spans over three decades with significant contributions to biomedical research. Dr. Riethmacher's research focuses on cancer development and progression, inflammatory bowel disease, and the application of mouse models in studying disease development. Her work has increasingly centered on periostin, a matricellular protein that plays crucial roles in inflammation, allergy, and cancer progression. She has made significant contributions to understanding the role of periostin in inflammatory bowel disease, bladder cancer, and its interactions with the CCL5-CCR5 axis. Her research has evolved from early work on signal transduction during development using mouse models to current investigations of cancer mechanisms and inflammatory processes. Her recent publications demonstrate a strong focus on the role of periostin in various disease contexts, particularly inflammatory bowel disease and cancer. This work has revealed important connections between periostin expression, immune regulation, and disease progression. Her research bridges basic science with potential clinical applications, particularly in understanding disease mechanisms that could lead to new therapeutic approaches. Dr. Riethmacher has received significant research funding for her work, including as Principal Investigator on grants related to genetically engineered microbiome treatments for inflammatory bowel disease and expanding the therapeutic landscape of CCR5 blockade. She has also served as Co-PI on multiple grants studying periostin in bladder cancer, colon cancer, and inflammatory bowel disease. As an educator, Dr. Riethmacher is heavily involved in supervising MD students, master's students, and PhD candidates in their research. She has supervised diploma and PhD students throughout her career, demonstrating a strong commitment to training the next generation of scientists and clinicians.

Olga Latinovicمشاهده پروفایل

استادیار مدعو

• Virology
• Immunology
• HIV-1 Entry Inhibition
• +۴ مورد دیگر

Olga S. Latinovic, PhD, MSc, MBA, MSc is an Adjunct Assistant Professor in the Department of Microbiology and Immunology at the Institute of Human Virology , affiliated with the University of Maryland School of Medicine . Her research focuses on novel antiretroviral therapy strategies targeting HIV-1 entry mechanisms via the CCR5 coreceptor , utilizing humanized mouse models to validate drug combinations for clinical translation. Education: PhD, Lehigh University (2006) Master of Science, Lehigh University (2001) Master of Business Administration, University of Baltimore (2020) Master of Science in Health Care, University of Baltimore (2020) Research Interests: Dr. Latinovic investigates HIV-1 entry inhibition through CCR5-targeting drugs, focusing on minimizing side effects while enhancing therapeutic synergy. Her work spans in vivo model development , drug combination validation , and cross-disciplinary virology (including SARS-CoV-2 receptor analysis). Scientific Contributions: Key studies include CCR5 population dynamics in humanized models (2022), cART intensification with CCR5 inhibitors (2021), and SARS-CoV-2 receptor expression in neuronal cells (2021). Earlier work explored FLSC IgG1 fusion proteins (2016) and Mycoplasma-DnaK oncogenicity (2018).

Jason Dufourمشاهده پروفایل

دانشیار

• Infectious Disease Research
• Virology
• Immunology
• +۴ مورد دیگر

Jason Dufour, DVM, DACLAM, is an Associate Professor of Medicine and Assistant Director for Clinical and Research Medicine at the Tulane National Primate Research Center. He holds a BS and DVM from Louisiana State University. His research focuses on infectious diseases (including SIV and COVID-19), gluten-sensitive enteropathy, and gene therapy applications in non-human primate models. His work spans virology, immunology, and veterinary medicine, with significant contributions to vaccine development, viral pathogenesis, and translational medicine. Key research interests include: Simian immunodeficiency virus (SIV) pathogenesis COVID-19 vaccine adjuvants and efficacy Gluten-induced enteropathy in macaques Gene therapy for genetic disorders Alcohol's impact on immune responses Publications highlight advancements in viral transmission blocking (e.g., CCR5 inhibitors), vaccine efficacy, and understanding disease mechanisms in non-human primate models. His clinical work includes managing primate health and surgical interventions for conditions like degenerative joint disease and vascular complications. Dr. Dufour collaborates on NIH-funded studies and has pioneered translational research linking basic science to clinical applications. His expertise bridges veterinary medicine, immunology, and infectious disease research, making significant contributions to biomedical science.

Eric Belin de Chantemeleمشاهده پروفایل

استاد

• Cardiovascular Disease
• Metabolic Syndrome
• Endothelial Dysfunction
• +۵ مورد دیگر

Eric Belin de Chantemele is a Regents' Professor at the Medical College of Georgia , Augusta University, with joint appointments in the Department of Medicine and Department of Physiology . Holding a Ph.D. in Cardiovascular Science from Université Lyon I, his research focuses on the interplay between metabolic disorders (obesity, diabetes, HIV) and cardiovascular disease , particularly the role of leptin in vascular dysfunction and hypertension. His work emphasizes sex-specific mechanisms , showing how leptin and progesterone interact through mineralocorticoid receptors to drive disease in females. He has led studies on NADPH oxidase 1 , CCR5 inhibition , and endothelial NOX1-PPARγ pathways . Recent publications include investigations into antiretroviral therapy-induced vascular injury and leptin replacement in lipodystrophy . Scientific Awards : Distinguished Mentor Award (2023) Charles Bates Research Award (2023) Henry Pickering Bowditch Award (2020) Established Investigator Award, AHA (2019) Faculty Senate Award for Young Outstanding Basic Science Faculty (2016) He chairs committees at the Vascular Biology Center and serves on editorial boards. His 15 most recent articles span topics from HIV-cardiovascular interactions to oxidative stress in metabolic disease , with keywords in diabetes, hypertension, sex differences, and HIV .

Denis Bulaninمشاهده پروفایل

استادیار

• Cancer Stem Cell Research
• CCR5 Receptor Blockade
• Targeted Drug Delivery
• +۶ مورد دیگر

Denis Bulanin is an Assistant Professor at the School of Medicine, Nazarbayev University , specializing in Biomedical Sciences . He actively teaches courses across MD, Nursing Bachelors, and MMM programs. Human Genetics (MD program) Introduction to Human Genetics (Nursing Bachelors) Molecular Basis of Genetic Disease (MMM program) Developmental Biology (MMM program) Research Methods in Molecular Medicine (MMM program) His research focuses on Cancer Stem Cell Biology and CCR5 Receptor Blockade , with emphasis on targeted therapies and molecular mechanisms. Key projects include: 2025-2027: CCL5-based inhibitors for prostate cancer progression (PI) 2024-2026: Rectal drug delivery system for CRC therapy (Co-PI) 2022-2024: Evaluation of CCR5 inhibitors in breast cancer (PI) 2021-2023: CCR5 blockade and CCL5 engineering (Co-PI) Publications span colorectal cancer stem cells (2015, 2019), oxidative stress in aging (2020), and in vitro drug screening (2023). Collaborations include institutions in Kazakhstan, Italy, and the US, with grant funding from Kazakh government programs.

Jaden Jungo Junمشاهده پروفایل

استادیار

• Medicinal Chemistry
• Oncology Drug Development
• Cannabinoid Receptor Modulators
• +۴ مورد دیگر

Jaden Jungo Jun is an Assistant Professor (Research) in the Department of Pharmaceutical Sciences at the University of Pittsburgh School of Pharmacy since August 2018. His expertise spans organic and medicinal chemistry, with over 15 years of experience in drug discovery across government (NIH), industry (GSK), and academic settings. He focuses on developing small-molecule inhibitors for oncology targets, particularly p62-multiple myeloma, cannabinoid receptor modulators, and renal fibrosis therapies. Education: PhD in Pharmaceutical Sciences (specific program details not explicitly stated in text). Notable award: Department of Defense (DoD) Breast Cancer Research Program (BCRP) Scholarship (2004–2005). Research interests include synthetic strategies for biologically active compounds, drug design targeting cancer and HIV, and collaborative projects with global scientists. Over 20 peer-reviewed publications and presentations at major conferences such as the American Chemical Society National Meetings highlight his contributions to medicinal chemistry and organic synthesis techniques. His work emphasizes multi-step synthesis, small molecule design, and team leadership in NIH-funded and university grants. Active in mentoring and accepting graduate students for research in drug discovery and organic chemistry.

• Tumor Immunology
• Immunotherapy
• Translational Medicine
• +۳ مورد دیگر

Professor Dr. Dirk Jäger is the Executive Director of the National Center for Tumor Diseases (NCT) Heidelberg and the Director of the Department of Medical Oncology at Heidelberg University Hospital. He oversees the clinical sector of NCT Heidelberg and leads translational research on immunotherapy, tumor immunology, and clinical trials for cancer treatment. Education: Medical training at the University of Lübeck and Freiburg; PhD in surgery from Freiburg University. Research: Focus on tumor antigen discovery, immune cell targeting, anti-CCR5 therapy, and combining radiation with immunotherapy. His work bridges preclinical studies and clinical application, particularly in colorectal cancer and melanoma. Awards: Recipient of the 2006 Investigator Award from the Cancer Research Institute.

• Immunology
• Immunopharmacology
• Oncology
• +۲ مورد دیگر

Dr. Tamara Muliaditan-de Koning is an Assistant Professor in the Department of Pharmacology at Utrecht University's Faculty of Science. Her research focuses on immunological and pharmacological approaches to cancer therapy, emphasizing T-cell engineering, macrophage biology, and tumor microenvironment dynamics. Research Expertise: Immunology and immunopharmacology mechanisms Oncogenic signaling pathways in solid tumors CAR-T cell optimization for cancer immunotherapy Metabolic regulation of immune cells Macrophage-mediated tumor angiogenesis and metastasis Her recent publications (2017–2023) demonstrate a consistent focus on translational oncology, with recurring themes in: (1) Engineering enhanced CAR-T cells for solid tumors, (2) Deciphering macrophage roles in chemotherapy resistance, and (3) Repurposing therapeutics to disrupt tumor-immune crosstalk. Work frequently appears in high-impact journals including Nature Communications , Science Advances , and Cell Reports Medicine .

Anja Muellerمشاهده پروفایل

استاد

• Cell Signaling
• Chemokine Receptors
• Cancer Biology
• +۳ مورد دیگر

Anja Mueller is a Professor and Head of School at the School of Chemistry, Pharmacy and Pharmacology, University of East Anglia. She holds a Biology degree from the University of the Saar (1995) and a PhD in Virology from the University Hospital Homburg/Saar (1999). Her career includes postdoctoral research at the University of Reading and Imperial College London before joining UEA in 2004 as Lecturer in Molecular Pharmacology, progressing to Senior Lecturer (2009) and Professor (2020). Her research focuses on chemokine receptors (e.g., CCR5, CXCR4) as GPCRs involved in HIV co-receptor functions and cancer cell migration. Key areas include receptor regulation, signaling pathways (e.g., calcium flux, PKC/PKD activation), and therapeutic target development. Active projects include collaborations on antimicrobial cyclic peptides and cancer drug discovery (e.g., Royal Commission Fellowship). Major contributions include identifying signaling networks in chemotaxis and developing fluorescent tools like IS4-FAM for CXCR4 studies. She coordinates the Applied Immunology and Infectious Diseases module and participates in initiatives addressing race relations in science. Over 15 former students have graduated under her supervision, contributing to her lab’s expertise in molecular pharmacology and cell migration mechanisms.

Christopher W. Petersonمشاهده پروفایل

عضو هیئت علمی

• Hematopoietic stem cell transplantation
• T-cell gene therapy
• HIV cure research
• +۵ مورد دیگر

Christopher W. Peterson, Ph.D., serves as a Research Associate Professor in the Division of Hematology and Oncology at the University of Washington and as a Staff Scientist in the Clinical Research Division at Fred Hutchinson Cancer Center. His academic journey includes a Ph.D. from the University of Utah and fellowships at both the UW Department of Global Health and Fred Hutch. Dr. Peterson's primary research focuses on developing gene therapy strategies for latent HIV-1 infection. His work centers on T cell, B cell, and hematopoietic stem cell gene therapy and gene editing approaches to target persistently-infected cells that remain despite antiretroviral therapy. He extends these approaches to other diseases that evade immune detection, including various viruses and cancers. His research prioritizes developing curative therapies that are both safer and more affordable than lifelong antiretroviral treatment, with special attention to applicability in resource-limited settings where HIV prevalence is high. His recent publications (2021-2024) demonstrate a strong focus on CAR T-cell therapies for HIV persistence, gene editing in large animal models, and innovative approaches to targeting viral reservoirs. His work bridges basic science with translational applications, particularly emphasizing non-human primate models to develop clinically relevant HIV cure strategies. Dr. Peterson's research program represents a critical intersection of virology, immunology, and gene therapy, with the ultimate goal of developing practical, globally accessible cures for HIV infection.